Novavax, Inc. $NVAX Stake Lowered by Aberdeen Group plc

Aberdeen Group plc decreased its stake in Novavax, Inc. (NASDAQ:NVAX) by 41.7% during the 2nd quarter, HoldingsChannel reports. The firm owned 37,188 shares of the biopharmaceutical company’s stock after selling 26,612 shares during the period. Aberdeen Group plc’s holdings in Novavax were worth $234,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVAX. Bayforest Capital Ltd bought a new position in Novavax during the 1st quarter worth $404,000. Kingstone Capital Partners Texas LLC bought a new position in shares of Novavax during the second quarter worth about $1,016,000. Park West Asset Management LLC acquired a new stake in shares of Novavax in the 1st quarter worth about $16,210,000. Shah Capital Management lifted its position in Novavax by 3.4% in the 2nd quarter. Shah Capital Management now owns 11,511,780 shares of the biopharmaceutical company’s stock valued at $72,524,000 after purchasing an additional 379,934 shares during the last quarter. Finally, Entropy Technologies LP bought a new stake in Novavax in the 1st quarter valued at about $191,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Trading Down 4.5%

Shares of NASDAQ:NVAX opened at $8.10 on Friday. The company has a 50 day moving average of $8.43 and a 200-day moving average of $7.36. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The firm has a market cap of $1.32 billion, a P/E ratio of 3.55, a P/E/G ratio of 0.11 and a beta of 2.74. Novavax, Inc. has a twelve month low of $5.01 and a twelve month high of $11.55.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.69. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business had revenue of $239.24 million for the quarter, compared to analyst estimates of $149.19 million. During the same quarter last year, the business earned $0.99 earnings per share. The business’s revenue for the quarter was down 42.4% on a year-over-year basis. As a group, analysts anticipate that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on NVAX shares. Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research report on Wednesday, October 8th. HC Wainwright assumed coverage on Novavax in a report on Thursday, August 28th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Bank of America restated an “underperform” rating and issued a $7.00 target price (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, Novavax currently has a consensus rating of “Reduce” and an average target price of $9.80.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.